The Philly-area founder of Proscia talks about starting young, finding purpose in healthcare and helping modernize the field.

Proscia is rewiring pathology to speed up the development of targeted therapies, accelerate diagnosis, and match more patients with the best course of treatment Funding led by global software investor ...

PHILADELPHIA, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Proscia ®, a global leader in AI-enabled pathology solutions for precision medicine, more than doubled its growth in 2024. The company enters 2025 ...

Proscia has inked a deal with a dermatopathology laboratory in a move designed to support its launch of the industry’s first comprehensive dermatopathology-specific digital pathology product in the ...

Proscia and Pramana will work to integrate Pramana's SpectralHT family of scanners with Proscia's Concentriq enterprise pathology platform. · GlobeNewswire Inc. Proscia Ready was established to help ...

A digital pathology company has raised $23 million in Series B funding as it seeks to push its cancer-detecting software into new markets. Philadelphia-based Proscia has made inroads into the research ...

Bioptimus’ H-optimus-0 Foundation Model Now Available with Proscia’s Concentriq® Embeddings for Rapid AI Development With 1.1 billion parameters, H-optimus-0 is the largest open-source AI foundation ...

Like most industries, COVID-19 disrupted digital pathology company Proscia‘s plans for growth. But unlike many, the virus accelerated operations for the eight-year-old Center City company. “Covid ...

The company’s Concentriq AP Dx software allows pathologists to make a primary diagnosis from an image on their computer screen, rather than a glass slide. The overwhelming majority of biopsies are ...

PHILADELPHIA, March 02, 2026 (GLOBE NEWSWIRE) -- Proscia ® has cemented its position as the top-performing digital pathology software company. A new report from KLAS Research awarded Proscia the ...

(MENAFN- GlobeNewsWire - Nasdaq) Expanding Proscia's precision medicine AI pipeline will help to optimize clinical trials and improve treatment decisions PHILADELPHIA and CHICAGO, June 25, 2024 (GLOBE ...